3843-97-8

Usage

Uses

Used in Chemical Synthesis:
Benzenamine, 5-chloro-2-ethylis used as a chemical intermediate for the synthesis of dyes, pharmaceuticals, and agrochemicals, due to its reactivity and ability to form a variety of compounds that are useful in these industries.
Used in Rubber Additives Production:
In the rubber industry, Benzenamine, 5-chloro-2-ethylis utilized as a chemical intermediate in the production of rubber additives, which enhance the properties of rubber, such as its durability and resistance to wear.
Used in Antioxidant Production:
Benzenamine, 5-chloro-2-ethylalso serves as a precursor in the synthesis of antioxidants, which are crucial in preventing the oxidation of materials, thereby extending their shelf life and performance.
Used in Organic Synthesis:
Benzenamine, 5-chloro-2-ethylhas potential applications in the broader field of organic synthesis, where it can be used as a reagent in various chemical reactions to produce a range of organic compounds.
Used in Chemical Reactions as a Reagent:
Benzenamine, 5-chloro-2-ethylfunctions as a reagent in chemical reactions, facilitating specific transformations that are essential in the synthesis of target molecules.

Upstream product

• 2001-16-3 4-chloro-1-ethyl-2-nitrobenzene 
• 74-85-1 ethene 
• 108-42-9 3-chloro-aniline 
• 622-98-0 4-chloro(ethylbenzene) 
• 589-16-2 4-aminoethylbenzene 
• 5805-89-0 N-(4-ethyl-3-nitrophenyl)acetamide 
• 51529-96-5 4-ethyl-3-nitroaniline 
• 3663-34-1 N-(4-ethylphenyl)acetamide 

Downstream Products

• 17746-69-9 5-chloro-2-ethylbenzonitrile 
• 103752-79-0 N-(5-chloro-2-ethylphenyl)acetamide 
• 774608-41-2 (5-chloro-2-ethylphenyl)boronic acid 
• 774608-40-1 4-chloro-1-ethyl-2-iodobenzene 
• 17746-68-8 5-Chlor-2-ethyl-benzoesaeure 

Relevant academic research and scientific papers

THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER

A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

Under the conditions of a solvent-free method of hydrogenation to synthesize haloarylamine

The invention provides a method for synthesising halogenated aromatic amine through hydrogenation in a solvent-free condition. The method comprises the following step of: carrying out a liquid-phase hydrogenation reaction on the halogenated aromatic nitro compound shown in formula (I) under the action of hydrogen, in the absence of a solvent and a dehalogenation inhibitor under the action of a carbon-supported large-particle-size precious metal catalyst to prepare the halogenated aromatic amine shown in formula (II). The method provided by the invention is capable of achieving the effect of inhibiting a hydrogenation dehalogenation side reaction in the case of not adding a dehalogenation inhibitor, is high in target product selectivity, and is capable of remarkably increasing the reaction speed.

SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS

The present invention relates to substituted pyrrole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Jak family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to pyrazolyl-pyrimidine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to pyrazolyl-pyrimidine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS

The present invention relates to substituted pyrimidinyl-pyrrole compounds of formula (I) which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular Janus kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.